MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-04-2026
Novo Nordisk A/S Cash and Cash Equivalents 2011-2026 | NVO
Annual Cash and Cash Equivalents Novo Nordisk A/S
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26.5 B | 15.7 B | 14.4 B | 12.7 B | 10.7 B | 12.2 B | 15.4 B | - | - | - | - | - | - | - | - |
All numbers in DKK currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 26.5 B | 10.7 B | 15.4 B |
Quarterly Cash and Cash Equivalents Novo Nordisk A/S
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 10.7 B | - | - | - | 12.2 B | - | - | - | 15.4 B | - | - | - | 15.6 B | - | - | - | 17.2 B | - | - | - | 18.5 B | - | - | - | 15.8 B | - | - | - | 13.7 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in DKK currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 18.5 B | 10.7 B | 14.9 B |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
34.8 M | $ 3.85 | 3.22 % | $ 9.26 B |  Australia |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.66 B | $ 325.52 | -2.36 % | $ 42.6 B | USA |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
98.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
18.3 M | $ 8.05 | 8.49 % | $ 79.6 M | USA |
 |
Allakos
ALLK
|
66.4 M | - | - | $ 28.6 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M |  Israel |
 |
Midatech Pharma plc
MTP
|
8.53 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Applied Therapeutics
APLT
|
49.9 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
29 K | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
170 M | $ 21.88 | 0.92 % | $ 1.02 B | USA |
 |
Burford Capital Limited
BUR
|
322 M | $ 4.71 | -0.53 % | $ 766 M | Britain |
 |
Cabaletta Bio
CABA
|
83 M | $ 3.49 | 2.65 % | $ 351 M | USA |
 |
CymaBay Therapeutics
CBAY
|
207 M | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
7.68 B | $ 101.45 | 1.99 % | $ 27.2 B | Germany |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
7.31 M | - | 5.93 % | $ 314 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 3.15 | -0.63 % | $ 5.19 M | Israel |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
8.91 M | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
185 M | $ 1.38 | -10.97 % | $ 355 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
121 M | $ 4.22 | -0.59 % | $ 451 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
42.9 M | $ 23.88 | -2.85 % | $ 3.04 B | USA |
 |
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
104 M | $ 1.53 | 2.35 % | $ 407 M | Britain |
 |
Aptose Biosciences
APTO
|
935 K | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
6.6 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
16.2 M | - | -16.75 % | $ 25.8 M | USA |
 |
AVROBIO
AVRO
|
98 M | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
28.9 M | - | - | $ 25.3 M | USA |
 |
Celldex Therapeutics
CLDX
|
28.9 M | $ 33.66 | -0.63 % | $ 2.24 B | USA |
 |
bluebird bio
BLUE
|
222 M | - | - | $ 546 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
7.2 M | $ 2.7 | -1.81 % | $ 1.2 M | USA |
 |
AstraZeneca PLC
AZN
|
5.71 B | - | - | $ 96.9 B | Britain |